WNY Asset Management LLC Takes $729,000 Position in Bristol Myers Squibb Company $BMY

WNY Asset Management LLC acquired a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 12,655 shares of the biopharmaceutical company’s stock, valued at approximately $729,000.

Several other institutional investors have also added to or reduced their stakes in BMY. Bank OZK acquired a new stake in Bristol Myers Squibb during the 2nd quarter valued at approximately $474,000. Old North State Trust LLC acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter worth approximately $725,000. Caitlin John LLC acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter worth approximately $220,000. Equitable Holdings Inc. bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at $7,303,000. Finally, Centaurus Financial Inc. bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at $637,000. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Stock Performance

NYSE:BMY opened at $66.93 on Friday. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $68.64. The company has a fifty day moving average of $61.51 and a 200-day moving average of $59.64. The firm has a market capitalization of $136.73 billion, a P/E ratio of 14.74, a P/E/G ratio of 0.18 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. Bristol Myers Squibb’s revenue was up 5.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.8%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is 55.51%.

Insider Activity at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.05% of the stock is currently owned by corporate insiders.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The FDA approved Zenbexus (iberdomide), BMY’s first-in-class CELMoD therapy, for adults with relapsed or refractory multiple myeloma in combination with Darzalex and dexamethasone. The approval adds a potential oncology growth driver and expands BMY’s treatment portfolio in a major cancer market. New FDA Approval Gives Bristol-Myers Squibb Another Potential Oncology Growth Catalyst
• Positive Sentiment: Zenbexus received accelerated approval based on improved minimal residual disease-negative complete response rates. As the first approved CELMoD therapy in this setting, it could strengthen BMY’s competitive position in multiple myeloma, although continued approval depends on confirmatory evidence. Zenbexus First-in-Class CELMoD Approval
• Positive Sentiment: BMY is extending clinical development of deucravacitinib, signaling longer-term ambitions in autoimmune diseases and potentially broadening its growth pipeline beyond oncology. Bristol Myers Squibb Extends Deucravacitinib Program
• Neutral Sentiment: Camzyos continues to gain momentum, but its ability to offset patent pressures on older products depends partly on an upcoming FDA decision regarding adolescent use and competition from rival heart drugs. Can Camzyos Growth Offset Bristol Myers Patent Pressures?
• Negative Sentiment: BMY ended its Cellares partnership after concluding that the Cell Shuttle platform could not support commercial-scale manufacturing of Breyanzi. The decision raises questions about manufacturing capacity and the pace of Breyanzi growth, despite avoiding further spending under the agreement valued at up to $380 million. Bristol-Myers Squibb’s Cellares Exit Raises Questions Over Breyanzi Growth
• Negative Sentiment: Senior Vice President Phil Holzer sold 500 BMY shares for approximately $33,750, reducing his holdings by 2.88%. The small transaction is generally a limited signal, but may add modest caution after the stock’s recent advance. Bristol Myers Squibb SVP Sells 500 Shares
• Negative Sentiment: A patent dispute involving Cytokinetics creates additional legal uncertainty around BMY’s products and could increase future litigation or commercial risks. What Does Bristol Myers Squibb Face After Zenbexus Approval and Patent Action?

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Guggenheim reissued a “buy” rating and set a $75.00 target price (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Piper Sandler began coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They set an “overweight” rating on the stock. Royal Bank Of Canada increased their price target on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “sector perform” rating in a report on Friday, July 31st. JPMorgan Chase & Co. boosted their price objective on Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $59.00 target price (up from $54.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb presently has an average rating of “Moderate Buy” and a consensus target price of $66.06.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.